JP2022538642A5 - - Google Patents
Info
- Publication number
- JP2022538642A5 JP2022538642A5 JP2021577641A JP2021577641A JP2022538642A5 JP 2022538642 A5 JP2022538642 A5 JP 2022538642A5 JP 2021577641 A JP2021577641 A JP 2021577641A JP 2021577641 A JP2021577641 A JP 2021577641A JP 2022538642 A5 JP2022538642 A5 JP 2022538642A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- treatment
- lmtx
- therapeutic composition
- neurotransmitter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909493.7A GB201909493D0 (en) | 2019-07-01 | 2019-07-01 | Therapeutic interactions |
| GB1909493.7 | 2019-07-01 | ||
| PCT/EP2020/068422 WO2021001380A1 (en) | 2019-07-01 | 2020-06-30 | Therapeutic interactions of leucomethylthioninium |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538642A JP2022538642A (ja) | 2022-09-05 |
| JP2022538642A5 true JP2022538642A5 (https=) | 2023-07-10 |
| JP7638915B2 JP7638915B2 (ja) | 2025-03-04 |
Family
ID=67540109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577641A Active JP7638915B2 (ja) | 2019-07-01 | 2020-06-30 | ロイコメチルチオニニウムの治療上の相互作用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230031369A1 (https=) |
| EP (1) | EP3989954A1 (https=) |
| JP (1) | JP7638915B2 (https=) |
| KR (1) | KR20220027203A (https=) |
| CN (1) | CN114126622A (https=) |
| AU (1) | AU2020298758A1 (https=) |
| BR (1) | BR112021025256A2 (https=) |
| CA (1) | CA3143790A1 (https=) |
| GB (1) | GB201909493D0 (https=) |
| IL (1) | IL289338B1 (https=) |
| MX (1) | MX2021015292A (https=) |
| WO (1) | WO2021001380A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7073330B2 (ja) | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| FI4385512T3 (fi) | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| AU2008265045B2 (en) | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| CA2701075C (en) | 2007-10-03 | 2019-02-12 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines. |
| EP2227766A2 (en) | 2007-11-05 | 2010-09-15 | Wista Laboratories Ltd. | Systems for clinical trials |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| JP7073330B2 (ja) * | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| FI4385512T3 (fi) * | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
-
2019
- 2019-07-01 GB GBGB1909493.7A patent/GB201909493D0/en not_active Ceased
-
2020
- 2020-06-30 MX MX2021015292A patent/MX2021015292A/es unknown
- 2020-06-30 CN CN202080048557.6A patent/CN114126622A/zh active Pending
- 2020-06-30 JP JP2021577641A patent/JP7638915B2/ja active Active
- 2020-06-30 KR KR1020227003213A patent/KR20220027203A/ko not_active Ceased
- 2020-06-30 WO PCT/EP2020/068422 patent/WO2021001380A1/en not_active Ceased
- 2020-06-30 US US17/620,949 patent/US20230031369A1/en not_active Abandoned
- 2020-06-30 EP EP20739286.1A patent/EP3989954A1/en active Pending
- 2020-06-30 CA CA3143790A patent/CA3143790A1/en active Pending
- 2020-06-30 BR BR112021025256A patent/BR112021025256A2/pt unknown
- 2020-06-30 AU AU2020298758A patent/AU2020298758A1/en active Pending
-
2021
- 2021-12-23 IL IL289338A patent/IL289338B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519661A5 (https=) | ||
| JP2024516371A5 (https=) | ||
| JP2020500862A5 (https=) | ||
| JP2022191257A5 (https=) | ||
| JP2007509055A (ja) | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の経口投与 | |
| JP2022539185A5 (https=) | ||
| JP2022537047A5 (https=) | ||
| JP2019516684A5 (https=) | ||
| TW201622721A (zh) | Ｓ１ｐ調節劑之立即釋放劑量療法 | |
| JP2022538642A5 (https=) | ||
| JP2011505356A5 (https=) | ||
| JP2022554276A5 (https=) | ||
| JP2024507810A5 (https=) | ||
| JP2022531251A5 (https=) | ||
| JP2016537432A5 (https=) | ||
| JP2012510985A5 (https=) | ||
| JP2024503727A5 (https=) | ||
| JP2025118775A5 (https=) | ||
| JP2024520132A5 (https=) | ||
| JP2007530703A5 (https=) | ||
| JP2023502053A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| CN1243540C (zh) | 用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合 | |
| JP2023531930A5 (https=) | ||
| CA2684174C (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson |